Latest news and articles about drug pricing from NEX English
Vas Narasimhan, CEO of Novartis, warns that the drug pricing policy established by President Trump will have negative repercussions for both pharmaceutical companies and patients. The effects of these policies are expected to manifest in the next eighteen months.
The UK government has announced a new agreement with the United States aimed at increasing drug spending in the UK. This initiative is part of efforts to attract more investments from major pharmaceutical companies.
Eli Lilly's CEO, Dave Ricks, announced the company's opposition to the White House's efforts to legislate a 'most favored nation' policy for drug pricing. This comes as the U.S. administration seeks to affirm lower drug prices in the American market.